No ancillary finding is valid to distinguish a primary ovarian hepatoid carcinoma from metastatic hepatocellular carcinoma

Kwon, Jong-Hee; Kim, S. H.; Cho, Namhoon

doi:10.1111/j.1525-1438.2006.00646.x

Cited by 20 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oftheothertumourmarkers,especiallyCEAisoftenproducedbyHAC.PositivityforCEAwasobservedin50-100% of all published cases, occurring in all HAC of the pancreas [27,28],ovaries,andfallopiantube [21,[29][30][31][32][33][34][35][36],in86%ofthe gallbladdercases [10,22,23,37,38],andin51%ofthegastric HAC [7,8,10,11,24]. Our patient had normal CEA serum concentrations,butthetumourcellswereweaklystainedby CEAinconcordancewiththeotherpublishedHACcaseof theperitonealcavity [15].Noticeablefordiagnosticreasonsis thepositivityforCEA,AFP,andCA125orthedetectionof elevatedserumlevelsofCA125inovarianHAC [21,29,[31][32][33][34][35][36].TheCEAstainingis,however,oflittlevaluefordifferentiationbetweenHACandHCC,asthemajorityofHCCare alsoCEA-positive [39].…”

Section: Resultsmentioning

confidence: 99%

Hepatoid Adenocarcinoma – Review of the Literature Illustrated by a Rare Case Originating in the Peritoneal Cavity

Metzgeroth¹,

Ströbel

Baumbusch³

et al. 2010

Onkologie

107

106

View full text Add to dashboard Cite

Hepatoid adenocarcinoma (HAC) is a rare and aggressive extrahepatic tumour, morphologically mimicking hepatocellular carcinoma (HCC). However, immunophenotype and location are heterogeneous. We report the case of a 21-year-old man with HAC of the peritoneal cavity and summarize data from the 261 HAC cases published so far. The most common HAC locations were stomach (63%), ovaries (10%), lung (5%), gallbladder (4%), pancreas (4%), and uterus (4%). With the exception of gallbladder HAC, there was a male predominance (M:F = 2.4:1). Median age was 65 years (range 21–88). Fatigue, weight loss, abdominal masses, and pain were common findings. One-year survival was 55% and median overall survival 11 months (range 0.1–102). The outstanding diagnostic feature of HAC is positivity for alphafetoprotein (AFP) (88%), HepPar1 (63%), and EpCAM antibodies HEA125 or MOC31 which show no reactivity with hepatocytes. Due to the beneficial effect of sorafenib in HCC and strong activation of EGFR, ERK1 and AKT1, our patient received sorafenib. Despite temporary clinical improvement, he died 6 months after the diagnosis. The diagnostic panel of HAC should include AFP, HepPar1, and EpCAM antibodies. EpCAM reactivity excludes HCC. HAC has a poor prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Hepatoid Adenocarcinoma – Review of the Literature Illustrated by a Rare Case Originating in the Peritoneal Cavity

Metzgeroth¹,

Ströbel

Baumbusch³

et al. 2010

Onkologie

107

106

View full text Add to dashboard Cite

show abstract

“…Among the nine patients that were examined for bile canalicular structures, four revealed positive results; therefore, we do not consider this to be a rare characteristic of HCO. Electron microscopy identified abundant mitochondria that possess lamella cristae with one or more electron-dense matrix granule, distended smooth endoplasmic reticulum-formed vesicles, a tight junction with few desmosomes and no microvilli, a rudimentary canaliculi, occasional lipid droplets and an inconspicuous golgi body and rough endoplasmic reticulum (14). During immunostaining, AFP, which is the hallmark of the tumor, was positive in all cases.…”

Section: Discussionmentioning

confidence: 90%

“…Although they may possess features resembling HCO, none of these tumors demonstrate AFP staining except in one case of endometrioid carcinoma where transformation of an endometrioid carcinoma to a yolk sac tumor occurred (19). Ovarian metastatic hepatocellular carcinoma should also be excluded, although to date there is no means of distinguishing between the two tumors (14).…”

Section: Discussionmentioning

confidence: 99%

“…The two basic diagnostic criteria are abundant eosinophilic cytoplasm of the tumor cells that resemble hepatocellular carcinoma, and positive immunohistochemical AFP staining (2). HCO has been known for 25 years, but to date, only 24 cases have been reported (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19). The clinical features are listed in Table I and II.…”

Section: Discussionmentioning

confidence: 99%

“…CK19 and CK20, which are commonly positive in normal gastrointestinal epithelial cells, bile duct cells and certain adenocarcinomas, including ovarian surface epithelial carcinomas, but negative in normal hepatocytes and hepatocellular carcinomas, may occasionally be positive in HCO. CK7 was positive in certain cases (8,12,14), and a diffusely positive staining for CK7 is considered to be highly consistent with HCO (14). The expression profiles of CK reflect the origin of HCO (11), and the degree of staining of hepatocyte paraffin (Hep Par) 1 may be related to the differentiation of the tumor.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatoid carcinoma of the ovary: A case report and review of the literature

2012

View full text Add to dashboard Cite

Abstract. Hepatoid carcinoma of the ovary is a type of tumor resembling hepatocellular carcinoma that arises from the ovary. Hepatoid carcinoma patients are predominantly elderly females ranging between 35 and 78 years of age, with an average age of 56 years. It was suggested that, microscopically, bile canalicular structures are rare, but among nine cases examined for bile canalicular structures, four demonstrated a positive result. Here, we report a case of a 55-year-old female who presented to the Second Xiangya Hospital, Changsha, China, with lower abdominal pain, abdominal distention and increasing abdominal girth. The patient underwent total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, tumor debulking and postoperative chemotherapy. A mass in the left ovary measuring approximately 11 cm in diameter was identified. Microscopic and immunohistochemical results suggested that it was a hepatoid carcinoma of the left ovary.

show abstract

Cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy

Cowan

VandenBussche

2018

Cancer Cytopathology

View full text Add to dashboard Cite

Initial evaluation of patients presenting with a suspected malignancy without a clear clinical or radiologic impression of a primary site (so-called cancer of unknown primary, or CUP) frequently includes fine needle aspiration (FNA) to both establish a diagnosis and procure tissue for additional studies. Careful management of limited specimen material is especially important in the modern era, when molecular studies may take precedence over a more definitive tissue diagnosis. This review summarizes our practice habits when encountering a CUP. Broadly, key morphologic patterns in context of patient history and clinical-radiologic impression should guide the selection of a limited panel of IPOX stains to establish first a broad lineage. Subsequently 1-2 site-specific markers may be used to confirm the diagnosis. In difficult cases, it is helpful to convey the situation to the treating physicians, who may prefer to prioritize molecular testing over pursuit of a more definitive diagnosis. Prudent choice of immunoperoxidase (IPOX) studies, based on both key cytomorphologic criteria and continued communications with the clinical team regarding their needs for treatment planning, is critical in CUP cases.

show abstract

No ancillary finding is valid to distinguish a primary ovarian hepatoid carcinoma from metastatic hepatocellular carcinoma

Cited by 20 publications

References 9 publications

Hepatoid Adenocarcinoma – Review of the Literature Illustrated by a Rare Case Originating in the Peritoneal Cavity

Hepatoid Adenocarcinoma – Review of the Literature Illustrated by a Rare Case Originating in the Peritoneal Cavity

Hepatoid carcinoma of the ovary: A case report and review of the literature

Cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy

Contact Info

Product

Resources

About